Abstract
Tumor secreted proteins/peptides (tumor secretome) act as mediators of tumor-host communication in the tumor microenvironment. Therefore, development of anti-cancer drugs targeting secretome may effectively control tumor progression. Novel techniques including a capillary ultrafiltration (CUF) probe and a dermis-based cell-trapped system (DBCTS) linked to a tissue chamber were utilized to sample in vivo secretome from tumor masses and microenvironments. The CUF probe and tissue chamber were evaluated in the context of in vivo secretome sampling. Both techniques have been successfully integrated with mass spectrometry for secretome identification. A secretome containing multiple proteins and peptides can be analyzed by NanoLC-LTQ mass spectrometry, which is specially suited to identifying proteins in a complex mixture. In the future, the establishment of comprehensive proteomes of various host and tumor cells, as well as plasma will help in distinguishing the cellular sources of secretome. Many detection methods have been patented regarding probes and peptide used for identification of tumors.
Keywords: Tumor secretion, ultrafiltration, secretome, drugs, mass spectrometry, tissue chamber
Recent Patents on Anti-Cancer Drug Discovery
Title: In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome
Volume: 3 Issue: 1
Author(s): Chun-Ming Huang, Teruaki Nakatsuji, Yu-Tseung Liu and Yang Shi
Affiliation:
Keywords: Tumor secretion, ultrafiltration, secretome, drugs, mass spectrometry, tissue chamber
Abstract: Tumor secreted proteins/peptides (tumor secretome) act as mediators of tumor-host communication in the tumor microenvironment. Therefore, development of anti-cancer drugs targeting secretome may effectively control tumor progression. Novel techniques including a capillary ultrafiltration (CUF) probe and a dermis-based cell-trapped system (DBCTS) linked to a tissue chamber were utilized to sample in vivo secretome from tumor masses and microenvironments. The CUF probe and tissue chamber were evaluated in the context of in vivo secretome sampling. Both techniques have been successfully integrated with mass spectrometry for secretome identification. A secretome containing multiple proteins and peptides can be analyzed by NanoLC-LTQ mass spectrometry, which is specially suited to identifying proteins in a complex mixture. In the future, the establishment of comprehensive proteomes of various host and tumor cells, as well as plasma will help in distinguishing the cellular sources of secretome. Many detection methods have been patented regarding probes and peptide used for identification of tumors.
Export Options
About this article
Cite this article as:
Huang Chun-Ming, Nakatsuji Teruaki, Liu Yu-Tseung and Shi Yang, In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (1) . https://dx.doi.org/10.2174/157489208783478694
DOI https://dx.doi.org/10.2174/157489208783478694 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design of Telomerase Inhibitors for the Treatment of Cancer
Current Pharmaceutical Design Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Injectable Thermosensitive Chitosan/Glycerophosphate-Based Hydrogels for Tissue Engineering and Drug Delivery Applications: A Review
Recent Patents on Drug Delivery & Formulation Targeted Radiosensitization in Prostate Cancer
Current Pharmaceutical Design Cannabis sativa L. Constituents and Their Role in Neuroinflammation
Current Bioactive Compounds Overview of Cantharidin and its Analogues
Current Medicinal Chemistry Dihydromyricetin Reduces TGF-β Via P53 Activation-dependent Mechanism in Hepatocellular Carcinoma HepG2 Cells
Protein & Peptide Letters Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
Current Signal Transduction Therapy Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers
Current Pharmaceutical Design Autophagy: Molecular Mechanisms and their Implications for Anticancer Therapies
Current Cancer Drug Targets Potential Therapeutic Targets in Energy Metabolism Pathways of Breast Cancer
Current Cancer Drug Targets Brain Tumor Detection Using Machine Learning and Deep Learning: A Review
Current Medical Imaging Small Molecules for Immunomodulation in Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry The PIK3CA Gene as a Mutated Target for Cancer Therapy
Current Cancer Drug Targets Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
Recent Patents on Anti-Cancer Drug Discovery Nanostructured Therapeutic Systems of PUFAs for the Treatment of Glioblastoma Multiforme
Current Drug Metabolism Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey
Current Pharmaceutical Biotechnology Radioprotective Effects of Plants from the Lamiaceae Family
Anti-Cancer Agents in Medicinal Chemistry [177Lu]-DOTA0-Tyr3-Octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma
Current Radiopharmaceuticals Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design